Inhibition of MELK Protooncogene as an Innovative Treatment for Intrahepatic Cholangiocarcinoma
Antonio Cigliano(University of Sassari), Kirsten Utpatel(University of Regensburg)
Cited by 13
Related Papers
Deregulated c-Myc requires a functional HSF1 for experimental and human hepatocarcinogenesis
|Oncotarget|2017|38
Wnt/β-Catenin-Pathway Alterations and Homologous Recombination Deficiency in Cholangiocarcinoma Cell Lines and Clinical Samples: Towards Specific Vulnerabilities
|Journal of Personalized Medicine|2022|7
Fatty Acid Synthase Promotes Hepatocellular Carcinoma Growth via S-Phase Kinase-Associated Protein 2/p27KIP1 Regulation
|Medicina|2024|7
HSF1 is a prognostic determinant and therapeutic target in intrahepatic cholangiocarcinoma
|Journal of Experimental & Clinical Cancer Research|2024|6
RASSF1A independence and early Galectin-1 upregulation in PIK3CA induced hepatocarcinogenesis: new therapeutic venues
|bioRxiv (Cold Spring Harbor Laboratory)|2021|1